<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523064</url>
  </required_header>
  <id_info>
    <org_study_id>4957/19/176</org_study_id>
    <nct_id>NCT04523064</nct_id>
  </id_info>
  <brief_title>iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump</brief_title>
  <acronym>POST-CABGDM</acronym>
  <official_title>SGLT2 Inhibitors in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary&#xD;
      artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The&#xD;
      revascularization surgery is commonly indicated to patients with multivessel coronary disease&#xD;
      and kidney injury is a prevalent complication in post operation. This work aims to evaluate&#xD;
      the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose&#xD;
      cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with&#xD;
      cardiopulmonary bypass&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Random Prospective Study non-blinded with 144 diabetics patients designated to myocardial&#xD;
      revascularization with cardiopulmonary bypass . 72 patients will be randomly set to usual&#xD;
      treatment provided by health care service and 72 patients will be randomly assigned treatment&#xD;
      based on ISGLT2 (Empaglifozin). Patients will receive treatment as set for 3 months until 3&#xD;
      days prior to surgery. Creatinine levels will be measured immediately after surgery and in&#xD;
      the following 3 days in post-op.&#xD;
&#xD;
      To evaluate the possibility to reduce the acute kidney injury in a randomized group treated&#xD;
      with therapy based on ISGLT2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 22, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>3 months</time_frame>
    <description>Development of post-CABG acute kidney injury according to RIFFLE or AKIN or KDIGO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>3 months</time_frame>
    <description>Development of atrial fibrillation during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary infection</measure>
    <time_frame>3 months</time_frame>
    <description>Development of pulmonary infection during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection of surgical site</measure>
    <time_frame>3 months</time_frame>
    <description>Development of infection of surgical site during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU readmission</measure>
    <time_frame>3 months</time_frame>
    <description>Transfer to ICU during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for IV insulin</measure>
    <time_frame>3 months</time_frame>
    <description>Need for IV insulin during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction Type 5</measure>
    <time_frame>3 months</time_frame>
    <description>Occurence of myocardial infarction type 5 during admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Bypass Surgery</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>SGLT2i (empagliflozin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 25 mg 1 time day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care treatment of diabetes patients in our center</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.</description>
    <arm_group_label>SGLT2i (empagliflozin)</arm_group_label>
    <other_name>Jardiance 25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Multivessel CAD documented by coronary angiography with formal indication for CRM.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eGFR &lt;30mL / min / 1.73m2 or dialysis therapy;&#xD;
&#xD;
          -  Inability to sign the informed consent form;&#xD;
&#xD;
          -  Contraindication to CABG on pump;&#xD;
&#xD;
          -  Need for urgent or emergency CABG;&#xD;
&#xD;
          -  Terminal or disabling illness with reduced life expectancy;&#xD;
&#xD;
          -  Pregnancy in progress.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos V Serrano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Coração - Hospital das Clinicas FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos V Serrano, MD, PhD</last_name>
    <phone>+551126615241</phone>
    <email>cvserranojr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Souza</last_name>
    <phone>+551126615241</phone>
    <email>simone.souza@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Sao Paulo Medical School - The Heart Institute</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabio G Pitta, M.D.</last_name>
      <phone>+5511991784180</phone>
      <email>fgpitta@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Simone Souza</last_name>
      <phone>+551126615352</phone>
      <email>simone.souza@incor.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio G Pitta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo G Lima, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Antonio M Cesar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Otávio C Auler Jr, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis A Dallan, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celia Strunz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Bolta, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo M Moreira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos V Serrano Jr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>SGLT2i</keyword>
  <keyword>CABG</keyword>
  <keyword>Acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

